Therapeutic Advances in Ophthalmology最新文献

{"title":"Erratum to \"Effect of laser peripheral iridotomy on contrast sensitivity using Spaeth/Richman Contrast Sensitivity test\".","authors":"","doi":"10.1177/25158414231158418","DOIUrl":"https://doi.org/10.1177/25158414231158418","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/25158414221078142.].</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231158418"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/52/10.1177_25158414231158418.PMC9941595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10770404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of silicone oil on retinal microcirculation after vitrectomy for rhegmatogenous retinal detachment evaluated by OCT angiography: a literature review.","authors":"Evita Evangelia Christou,&nbsp;Dimitrios Papaconstantinou,&nbsp;Konstantinos Droutsas,&nbsp;Maria Stefaniotou,&nbsp;Panagiotis Stavrakas,&nbsp;Stylianos Kandarakis,&nbsp;Petros Petrou,&nbsp;Ilias Georgalas","doi":"10.1177/25158414231174145","DOIUrl":"https://doi.org/10.1177/25158414231174145","url":null,"abstract":"<p><p>Silicone oil (SO) has been widely used as intravitreal tamponade agent for rhegmatogenous retinal detachment (RRD) and has been occasionally associated with incomplete retinal structural and functional recovery. The use of Optical Coherence Tomography Angiography (OCT-A) has recently attracted significant attention for detailed analysis of retinal capillary plexus and blood flow changes as predicting factors for postoperative outcomes. A detailed literature search was performed in PubMed database until October 2022. The following keywords were used: rhegmatogenous retinal detachment, silicone oil, optical coherence tomography angiography, macular microvasculature, peripapillary capillary plexus, vessel density, and foveal avascular zone. We identified and reviewed 19 studies referring to microcirculation alterations of the retinal capillary plexus as seen on OCT-A in eyes treated by vitrectomy with intravitreal SO for RRD. A comprehensive update revealed variability of microcirculation characteristics of the retinal capillary plexus including the macular and the peripapillary capillaries. Further studies are warranted to clarify the OCT-A values in an attempt to identify the potential effect of SO on retinal tissue in clinical practice. A review of the existing literature sheds light on the effect of SO on retinal capillary plexus and the potential impact on functional outcomes after vitrectomy for RRD. This article discusses important aspects of key publications on the topic, highlights the importance to identify distinct alterations of the microvasculature status, and proposes the need for further future research in this field.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231174145"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/ee/10.1177_25158414231174145.PMC10226327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9553558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of minimally invasive glaucoma surgery on the ocular surface and quality of life in patients with glaucoma.","authors":"Lee Jones,&nbsp;Natalia Maes,&nbsp;Umair Qidwai,&nbsp;Gokulan Ratnarajan","doi":"10.1177/25158414231152765","DOIUrl":"https://doi.org/10.1177/25158414231152765","url":null,"abstract":"<p><strong>Background: </strong>Minimally invasive glaucoma procedures are emerging as clinically effective and safe glaucoma management approaches; however, evidence regarding quality-of-life outcomes is limited.</p><p><strong>Objectives: </strong>To explore the impact of minimally invasive glaucoma surgery (MIGS) combined with phacoemulsification on patient-reported outcomes and clinical parameters related to ocular surface disease in people with glaucoma.</p><p><strong>Design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>Fifty-seven consecutive patients were examined prior to undergoing iStent combined with phacoemulsification with or without adjunctive endocyclophotocoagulation and at 4-month follow-up.</p><p><strong>Results: </strong>At follow-up, on average patients returned statistically significantly improved scores on glaucoma-specific (GQL-15, <i>p</i> < 0.001; GSS, <i>p</i> < 0.001), general health (EQ-5D, <i>p</i> = 0.02) and ocular surface PROMs (OSDI, <i>p</i> = 0.001). Patients were using fewer eye drops on average after MIGS compared with before surgery (1.1 ± 0.9 <i>versus</i> 1.8 ± 0.8; <i>p</i> < 0.001). Undergoing MIGS was associated with improved tear film break-up time (<i>p</i> < 0.001) and reduced corneal fluorescein staining (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>This retrospective audit shows quality of life and clinical parameters related to the ocular surface are improved following MIGS combined with phacoemulsification in patients previously treated with anti-glaucoma therapy.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231152765"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/07/10.1177_25158414231152765.PMC10107052.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9389944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study.","authors":"Yusuf Berk Akbas,&nbsp;Cengiz Alagoz,&nbsp;Semih Cakmak,&nbsp;Gokhan Demir,&nbsp;Nese Alagoz,&nbsp;Halil Ozgur Artunay","doi":"10.1177/25158414231195174","DOIUrl":"https://doi.org/10.1177/25158414231195174","url":null,"abstract":"<p><strong>Background: </strong>Diabetic macular edema (DME) is the most common cause of visual deterioration in patients with diabetes mellitus. Various treatment options have been used for DME, including intravitreal injection of steroids and anti-vascular endothelial growth factors.</p><p><strong>Objectives: </strong>To evaluate and compare the functional and anatomical outcomes of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) treatments in patients with DME.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Methods: </strong>Four hundred three eyes of 235 naïve patients who underwent IVR or IVA treatment for DME followed up to 36 months included in the study. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline, year 1, 2 and 3. Primary endpoint of the study was the change in BCVA and CMT each year from baseline and requirement of additional treatment (laser/steroid injection).</p><p><strong>Results: </strong>There were 198 eyes in IVR group and 205 eyes in IVA group. The changes in mean BCVA were 0.09 ± 0.32 <i>versus</i> 0.17 ± 0.41 Logarithm of the minimum angle of resolution (logMAR) (<i>p</i> = 0.042) at year 1, 0.09 ± 0.37 <i>versus</i> 0.12 ± 0.45 logMAR (<i>p</i> = 0.512) at year 2 and 0.13 ± 0.36 <i>versus</i> 0.15 ± 0.48 logMAR (<i>p</i> = 0.824) at year 3 in IVA and IVR groups, respectively. The baseline mean BCVA were lower (<i>p</i> = 0.004) in IVA group. The mean total number of injections was 7.93 ± 3.38 <i>versus</i> 7.42 ± 3.05 (<i>p</i> = 0.112).</p><p><strong>Conclusion: </strong>At year 1, change in mean BCVA was statistically significantly higher in IVA group; however this difference did not persist at years 2 and 3. Although the mean total number of injections was similar between groups, the requirement for adjuvant steroid treatment was significantly higher in ranibizumab group, which may affect the number of visits and treatment costs. Both ranibizumab and aflibercept treatments achieved a good long-term visual and anatomical response in DME patients.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231195174"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/23/10.1177_25158414231195174.PMC10464826.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of parafoveal and peripapillary vascular densities using optical coherence tomography angiography in children with thalassemia major.","authors":"Mehmet Emin Dursun,&nbsp;Leyla Hazar,&nbsp;Mine Karahan,&nbsp;Seyfettin Erdem,&nbsp;Sedat Ava,&nbsp;Veysiye Hülya Üzel,&nbsp;Birgül Dursun,&nbsp;Uğur Keklikçi","doi":"10.1177/25158414231162846","DOIUrl":"https://doi.org/10.1177/25158414231162846","url":null,"abstract":"<p><strong>Background: </strong>Thalassemia major (TM) is an inherited anaemia caused by faulty haemoglobin synthesis. Reducing serum iron levels using iron chelating agents is an important step in the treatment of TM, and the effects on the eye of both the disease and these agents can be determined by regular eye examination.</p><p><strong>Objectives: </strong>We evaluated macular and optic nerve vascular densities in children with TM and compared the results with healthy controls using optical coherence tomography angiography (OCTA).</p><p><strong>Design: </strong>This is a prospective study.</p><p><strong>Methods: </strong>A total of 30 children with TM and 30 healthy controls were included in the study. The area of the foveal avascular zone (FAZ) and the vascular densities (VD) of the optic nerve head (ONH), radial peripapillary capillary (RPC) and deep and superficial retinal vascular networks were measured using OCTA.</p><p><strong>Results: </strong>A statistically significant decrease in VD was observed in the whole image and the parafovea, superior hemi, superior and inferior parts of the superficial capillary plexus and in the whole image and the superior regions of the deep capillary plexus in the TM patient group compared with the control group (<i>p</i> < 0.05). A significant decrease in VD was also observed in the whole image and the inside disc, peripapillary, nasal, inferonasal and temporal regions of the ONH and in the whole image and the inside disc, peripapillary and inferonasal regions of the RPC network in patients with TM (<i>p</i> < 0.05). A significant positive correlation was observed between both serum ferritin levels and deferasirox dosage, on one hand, and both the superficial (<i>p</i> = 0.023 and <i>p</i> = 0.002, respectively) and deep FAZs (<i>p</i> = 0.015 and <i>p</i> = 0.045, respectively), on the other hand. A negative correlation was also found between the deferasirox dosage and the VDs of the superficial (<i>p</i> = 0.010) and deep (<i>p</i> = 0.001) foveal plexuses.</p><p><strong>Conclusion: </strong>Retinal VD and FAZ are affected in patients with TM. OCTA, which can noninvasively measure retinal VD in patients with TM, may be a useful tool for the early detection of retinal microvascular changes that may occur during the course of the disease.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231162846"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/a1/10.1177_25158414231162846.PMC10088408.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9310728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular biometry, anterior chamber morphometry, and their relationship with serum ferritin levels in children with beta thalassemia major.","authors":"Göksu Hande Naz Şimdivar,&nbsp;Tuğba Kurumoğlu Incekalan,&nbsp;Defne Ay Tuncel","doi":"10.1177/25158414231165824","DOIUrl":"https://doi.org/10.1177/25158414231165824","url":null,"abstract":"<p><strong>Background: </strong>Ocular biometry and anterior segment evaluations are important to determine ocular development and pathological changes, especially in thalassemia patients in Mediterranean countries such as Turkey.</p><p><strong>Objectives: </strong>The objectives of this study were to compare ocular biometry and anterior segment parameters in children with thalassemia major and healthy controls and to examine the relationship between ferritin levels, anthropometric measurements, and ocular parameters.</p><p><strong>Design: </strong>This is a prospective case-control study.</p><p><strong>Methods: </strong>The height, weight, body mass index, and occipitofrontal circumference values of the participants were recorded. Anterior and vitreous chamber depth, lens thickness, axial length, central corneal thickness, anterior chamber volume, iridocorneal angle, pupil diameter, and mean keratometry were measured. Measurements were compared between patients and healthy children, and between patients with ferritin levels above and below 1000 ng/mL.</p><p><strong>Results: </strong>This study included 40 patients and 45 controls. Height, weight, and body mass index were significantly lower while ferritin level and occipitofrontal circumference were significantly higher in patients compared with the controls (<i>p</i> < 0.001 for all). There were no statistically significant differences in the other ocular parameters (<i>p</i> > 0.05). In comparisons between patients with ferritin levels below (<i>n</i> = 15) and above 1000 ng/mL (<i>n</i> = 25), there were no significant differences in age, height, weight, body mass index, occipitofrontal circumference, or ocular parameters (<i>p</i> > 0.05). Occipitofrontal circumference and mean keratometry value were positively correlated in patients with ferritin levels below 1000 ng/mL (<i>r</i> = 0.573, <i>p</i> = 0.025), while body mass index was negatively correlated with pupil diameter in patients with ferritin levels above 1000 ng/mL (<i>r</i> = -0.469, <i>p</i> = 0.018).</p><p><strong>Conclusion: </strong>Children with thalassemia showed significant growth retardation and large occipitofrontal circumference but did not differ from controls in terms of biometrics and anterior segment morphology. Our results demonstrated a positive correlation between the occipitofrontal circumference and mean keratometry value in children with ferritin levels below 1000 ng/mL and a negative correlation between body mass index and pupil diameter in children with ferritin levels above 1000 ng/mL.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"15 ","pages":"25158414231165824"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/21/10.1177_25158414231165824.PMC10126650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9357084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal thickness in patients with systemic arterial hypertension: a systematic review and meta-analysis.","authors":"Konstantinos A Papathanasiou,&nbsp;Dimitrios Kazantzis,&nbsp;Dimitrios A Vrachatis,&nbsp;Sotiria G Giotaki,&nbsp;Eva Papaconstantinou,&nbsp;Menelaos Kanakis,&nbsp;Dimitrios Avramides,&nbsp;Spyridon Deftereos,&nbsp;Irini Chatziralli,&nbsp;Ilias Georgalas","doi":"10.1177/25158414221132825","DOIUrl":"https://doi.org/10.1177/25158414221132825","url":null,"abstract":"<p><strong>Background: </strong>The global burden of hypertension is constantly increasing with adverse cardiovascular and ocular sequelae. The association between elevated blood pressure and choroidal thickness (CT), as assessed via optical coherence tomography (OCT), is poorly understood.</p><p><strong>Objectives and design: </strong>Studies including hypertensive adults and normotensive controls undergoing OCT were evaluated for inclusion in this meta-analysis. The primary endpoint was CT difference between hypertensive and normotensive adults.</p><p><strong>Data sources and methods: </strong>We conducted a systematic review and after searching 1011 results from MEDLINE, ClinicalTrials.gov, medRxiv and Cochrane Library, six studies were deemed eligible and were pooled according to a random-effect model.</p><p><strong>Results: </strong>A statistically significant reduction in choroidal thickness was found in hypertensive adults (<i>n</i> = 454) as compared with normotensive controls (<i>n</i> = 365) [mean difference: -0.77; 95% confidence intervals: (-1.20, -0.34); <i>p</i> = 0.0004]. The main limitations of this meta-analysis are the relatively small population included and the high statistical heterogeneity (<i>I</i> ² = 87%) among the various studies. Of note, after excluding one study the heterogeneity was markedly reduced.</p><p><strong>Conclusion: </strong>Choroidal thickness is reduced among hypertensive subjects compared with normotensive controls. This finding mandates further examination in the context of long-term clinical outcomes.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":" ","pages":"25158414221132825"},"PeriodicalIF":2.5,"publicationDate":"2022-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/bf/10.1177_25158414221132825.PMC9643763.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40709287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA-based therapies in inherited retinal diseases.","authors":"Aniz Girach,&nbsp;Isabelle Audo,&nbsp;David G Birch,&nbsp;Rachel M Huckfeldt,&nbsp;Byron L Lam,&nbsp;Bart P Leroy,&nbsp;Michel Michaelides,&nbsp;Stephen R Russell,&nbsp;Juliana M F Sallum,&nbsp;Katarina Stingl,&nbsp;Stephen H Tsang,&nbsp;Paul Yang","doi":"10.1177/25158414221134602","DOIUrl":"https://doi.org/10.1177/25158414221134602","url":null,"abstract":"Inherited retinal diseases (IRDs) are a genetically and phenotypically heterogeneous group of genetic eye disorders. There are more than 300 disease entities, and together this group of disorders affects millions of people globally and is a frequent cause of blindness or low-vision certification. However, each type is rare or ultra-rare. Characteristically, the impaired vision in IRDs is due to retinal photoreceptor dysfunction and loss resulting from mutation in a gene that codes for a retinal protein. Historically, IRDs have been considered incurable and individuals living with these blinding conditions could be offered only supportive care. However, the treatment landscape for IRDs is beginning to evolve. Progress is being made, driven by improvements in understanding of genotype–phenotype relationships, through advances in molecular genetic testing and retinal imaging. Alongside this expanding knowledge of IRDs, the current era of precision medicine is fueling a growth in targeted therapies. This has resulted in the first treatment for an IRD being approved. Several other therapies are currently in development in the IRD space, including RNA-based therapies, gene-based therapies (such as augmentation therapy and gene editing), cell therapy, visual prosthetics, and optogenetics. RNA-based therapies are a novel approach within precision medicine that have demonstrated success, particularly in rare diseases. Three antisense oligonucleotides (AONs) are currently in development for the treatment of specific IRD subtypes. These RNA-based therapies bring several key advantages in the setting of IRDs, and the potential to bring meaningful vision benefit to individuals living with inherited blinding disorders. This review will examine the increasing breadth and relevance of RNA-based therapies in clinical medicine, explore the key features that make AONs suitable for treating genetic eye diseases, and provide an overview of the three-leading investigational AONs in clinical trials.","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":" ","pages":"25158414221134602"},"PeriodicalIF":2.5,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/69/10.1177_25158414221134602.PMC9643766.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40709288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy.","authors":"Alejandro Arboleda,&nbsp;Christopher N Ta","doi":"10.1177/25158414221134598","DOIUrl":"https://doi.org/10.1177/25158414221134598","url":null,"abstract":"<p><strong>Background: </strong>Neurotrophic keratopathy (NK) and limbal stem cell deficiency (LSCD) have high morbidity and require aggressive management to prevent permanent vision loss. Cenegermin, a recombinant human nerve growth factor, was approved by the Federal Drug Administration in 2018 for the treatment of NK.</p><p><strong>Objectives: </strong>To determine the efficacy and safety of cenegermin in the treatment of LSCD associated with NK.</p><p><strong>Design: </strong>Prospective cohort study.</p><p><strong>Methods: </strong>Patients diagnosed with LSCD and NK who had failed conventional treatment were enrolled in this prospective open-label study. Patients were treated with cenegermin for 8 weeks. The primary objective was to determine whether the area of abnormal epithelium decreased following treatment. Corneal sensation, visual acuity (VA), and LSCD severity were also evaluated.</p><p><strong>Results: </strong>Six eyes of 5 patients were included in the study. Cenegermin significantly improved the area of abnormal corneal epithelium in 5 of 6 eyes, measuring 73% of total corneal area at the initial visit and 48% at the final visit (<i>P</i> = .036). Corneal sensation improved in all patients, Cochet-Bonnet aesthesiometry measured 14.7 and 26.7 mm at the initial and final visit, respectively (<i>P</i> = .009). VA improved in 4 out of 6 eyes, with mean initial logMAR VA of 1.67 and final logMAR VA of 1.19 (<i>P</i> = .045). Finally, LSCD grading improved using the Aravena scoring system; however, this difference was not statistically significant (<i>P</i> = .14). One patient presented with an epithelial defect at baseline, which resolved following treatment. No patient withdrew from the study due to adverse effects.</p><p><strong>Conclusions: </strong>Cenegermin effectively improved the cornea epithelium, VA, and corneal sensation in patients with LSCD and NK who had failed prior treatment. Further studies are necessary to better understand the anatomical changes and to confirm our results with a larger randomized control trial.</p><p><strong>Registration: </strong>The study was registered at ClinicalTrials.gov with identifier NCT04552730 (https://clinicaltrials.gov/ct2/show/NCT04552730).</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":" ","pages":"25158414221134598"},"PeriodicalIF":2.5,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/17/10.1177_25158414221134598.PMC9638689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40454721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber.","authors":"Gulsah Gumus,&nbsp;Mustafa Berhuni,&nbsp;Cem Ozturkmen","doi":"10.1177/25158414221133772","DOIUrl":"https://doi.org/10.1177/25158414221133772","url":null,"abstract":"<p><strong>Background: </strong>Transient increase in intraocular pressure (IOP), changes in anterior chamber parameters, and changes in aqueous humor dynamics may occur after intravitreal injections because of intravitreal volume changes.</p><p><strong>Objective: </strong>In this observational study, we investigated the early effects of intravitreal bevacizumab (IVB) injection on IOP, central corneal thickness (CCT), corneal volume (CV), anterior chamber depth (ACD), and iridocorneal angle (ICA).</p><p><strong>Method: </strong>The patients who had one single-dose IVB (2.5 mg/0.1 mL) injection were included in the study. The patients underwent IOP, CCT, CV, ACD, and ICA measurements before and 1 h and 1 day after the injection. Pre-injection and post-injection values were compared.</p><p><strong>Results: </strong>Forty-two eyes of 42 patients were included in the study, and the mean age of patients was 60.1 ± 7.4 years. The mean IOP measurements before and after injection at 1 h and day 1 were 15 ± 2.4, 17.4 ± 2.4, and 14.7 ± 2.3, respectively. The mean IOP, CCT, and CV values 1 h after injection were significantly higher than pre-injection values (<i>p</i> < 0.05, <i>p</i> < 0.05, and <i>p</i> = 0.02, respectively). Conversely, mean ACD and ICA values 1 h after injection were significantly lower than pre-injection values (<i>p</i> = 0.01 for both). There were no statistically significant differences on the first day after injection for all parameters.</p><p><strong>Conclusion: </strong>IVB (2.5 mg/0.1 mL) injection causes transient increases in IOP and transient decreases in ACD and ICA at the first hour after injection. Related to elevation in IOP, CCT and CV may increase transiently. These changes return to baseline values on the first day after injection.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":" ","pages":"25158414221133772"},"PeriodicalIF":2.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/83/10.1177_25158414221133772.PMC9634187.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40470466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}